First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma

Richard D. Kim, Debashis Sarker, Tim Meyer, Thomas Yau, Teresa Macarulla, Joong Won Park, Su Pin Choo, Antoine Hollebecque, Max W. Sung, Ho Yeong Lim, Vincenzo Mazzaferro, Joerg Trojan, Andrew X. Zhu, Jung Hwan Yoon, Sunil Sharma, Zhong Zhe Lin, Stephen L. Chan, Sandrine Faivre, Lynn G. Feun, Chia Jui YenJean Francois Dufour, Daniel H. Palmer, Josep M. Llovet, Melissa Manoogian, Meera Tugnait, Nicolas Stransky, Margit Hagel, Nancy E. Kohl, Christoph Lengauer, Cori Ann Sherwin, Oleg Schmidt-Kittler, Klaus P. Hoeflich, Hongliang Shi, Beni B. Wolf, Yoon Koo Kang*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

166 Citations (Scopus)

Fingerprint

Dive into the research topics of 'First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science